Clinical Trial Update: Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year [Phase 3]

View source ↗

Summary

Phase 3 trial update on the efficacy and safety of subcutaneous secukinumab for moderate to severe chronic plaque-type psoriasis with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• To Severe Plaque-type Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate to Severe Plaque-type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2015-05-29